Alterity Therapeutics(ATHE) - 2026 Q2 - Quarterly Report

Exhibit 99.1 30 January 2026 Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 January 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and upda ...